This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Merrimack To Present Preclinical Data At The American Society Of Clinical Oncology (ASCO) 2014 Gastrointestinal Cancers Symposium

CAMBRIDGE, Mass., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that preclinical data on an analysis of HER2, HER3 and heregulin levels in gastric and gastroesophageal junction (GEJ) tumors will be presented at the American Society of Clinical Oncology 2014 Gastrointestinal Cancers Symposium (ASCO GI), January 16-18, 2014 at the Moscone West Building in San Francisco.

HER2 is a receptor that, when overexpressed in cancer cells, is linked to a poorer prognosis of disease due to its role in cellular growth and tumor survival. HER2 has the ability to dimerize with HER3, a receptor in the same family that has been implicated in the development of tumor resistance to selective cancer therapies. Levels of HER2, HER3 and heregulin (the ligand for the HER3 receptor) were analyzed to determine the prevalence of these potential mediators of resistance to cancer therapy in gastric and GEJ cancers.  

Merrimack has initiated a Phase 2 trial of MM-111, a bispecific antibody designed to inhibit HER3 in HER2 expressing tumors, in HER2-expressing gastric and GEJ cancers.

Poster Overview:

  • Potential regulators of HER2 activity in HER2-overexpressing gastric and gastroesophageal tumors: Analysis of HER3 and heregulin expression (Abstract ID #48, Poster Board B22)

General Poster Session A: Cancers of the Esophagus and Stomach

Thursday, January 16, 2014

12:00 – 2:00 p.m. PT, Level One, West Hall

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research throughout the research and development process. Merrimack currently has six targeted therapeutic oncology therapeutics in clinical development. For more information, please visit Merrimack's website at  www.merrimackpharma.com .

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

CONTACT: Media Contacts:
         
         Debbie Tseng, Merrimack
         617-441-7659
         dtseng@merrimackpharma.com
         
         Heather Gitlitz, Spectrum
         202-955-6222
         hgitlitz@spectrumscience.com

Merrimack logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,041.54 -190.48 -1.04%
S&P 500 2,104.20 -21.86 -1.03%
NASDAQ 5,032.7510 -56.6110 -1.11%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs